
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 10, 2026, 8:00 AM ET
Krystal Biotech will present at three investor conferences, from the Jefferies Global Healthcare Conference on November 17, 2026 to Citi's conference on December 2, 2026.
NASDAQ: $KRYSBiotech · Genetic medicinesProduct concentration and clinical risk
KRYS Stock Hub: Krystal Biotech News, VYJUVEK and Gene Therapy Pipeline
Q3 VYJUVEK net revenue reached $127.341M; Krystal reported $71.145M of operating income. Cash and investments totaled $1.194B at September 30. HALITE-1 data remain expected by year-end, while several eye and lung programs now have updated 2027 windows. Q3 2026 Form 10-Q · November 2 Q3 results and pipeline timing · November 2
Research Library · Biotech
Krystal Biotech: VYJUVEK Growth and the Genetic-Medicine Pipeline
Commercial performance, international access and clinical development · Research as of November 12, 2026
Next catalyst · company-guided clinical window
By year-end 2026 · KB111 HALITE-1 interim
Five patients are enrolled in the open-label Hailey-Hailey study. Q1 2027 is the separate planned FDA meeting after severity-scale validation; KB407 interim data are now expected H1 2027. Q3 results and pipeline timing · November 2
Before that window closes: Jefferies investor presentation, November 17 at 08:00 GMT. It is not an announced trial readout. Investor conference schedule · November 10
KRYS stock data: financial position and capital
Chart analysis · JC
Technical chart analysis of $KRYS with bull and bear scenarios on JC Just Charts.
Q3 VYJUVEK revenue
$127.341M
Quarter ended September 30
Q3 operating income
$71.145M
GAAP; net income $63.068M
Cash + investments
$1.194B
September 30; includes long-term securities
Operating cash flow
$246.420M
Nine months ended September 30
Common shares
29.633M
October 28 cover count
Repurchase ceiling
$400M
Authorization; no required purchases
Figures dated as shown. September cash and short-term investments alone total $911.851M; the broad $1.194B figure also includes long-term investments. Market value is basic, not fully diluted. Q3 2026 Form 10-Q · November 2
KRYS stock: profitable growth and a concentrated product base
VYJUVEK supplies reported product revenue. Early pipeline cohorts remain small, and the November update revised several clinical windows. Q3 2026 Form 10-Q · November 2 Q3 results and pipeline timing · November 2
▲ The constructive case
International revenue contributes to a profitable franchise with positive operating cash flow and substantial resources for development. The engineered HSV-1 platform has multiple potential applications. Q3 2026 Form 10-Q · November 2
▼ The cautious case
Nine-month U.S. sales declined modestly. New candidates must establish their own efficacy, safety and regulatory paths; a strong balance sheet does not resolve trial risk. Q3 2026 Form 10-Q · November 2 Q3 results and pipeline timing · November 2
Latest KRYS news
Nov 10, 2026
Krystal Biotech to present at upcoming investor conferences
Krystal Biotech management will take part in fireside chats and host investor meetings at the Jefferies Global Healthcare Conference in London on November 17, 2026, the 9th Annual Evercore Healthcare Conference in Coral Gables, Florida on December 1, 2026, and Citi's 2026 Global Healthcare Conference in Miami, Florida on December 2, 2026. Each presentation will be webcast live and archived on the Investors section of the company's website for at least 30 days.
KRYS stock catalysts: HALITE-1 and the updated 2027 calendar
- By year-end 2026 — KB111 HALITE-1 interim data. Q3 results and pipeline timing · November 2 Expected clinical data
- November 17, 2026 — Jefferies presentation at 08:00 GMT. Investor conference schedule · November 10 Scheduled investor event
- By year-end 2026 — Spain pricing decision; Switzerland application. Q3 results and pipeline timing · November 2 Company targets
- Early 2027 — Italy VYJUVEK launch. Q3 results and pipeline timing · November 2 Expected
- Q1 2027 — KB111 FDA meeting after scale validation. Q3 results and pipeline timing · November 2 Planned interaction
- February 2027 — KB803 last patient visit, topline shortly thereafter. Q3 results and pipeline timing · November 2 Company forecast
- H1 2027 — KB407 repeat-dose interim. Q3 results and pipeline timing · November 2 Expected
- 2027 — KB801 and KB408 data; KB304 Phase 2 start. Q3 results and pipeline timing · November 2 Year-level forecasts
FDA designations and CID meetings are development interactions. No investigational product is presented as approved, and study-completion dates are distinct from readout dates. Q3 2026 Form 10-Q · November 2
VYJUVEK: U.S., Europe and Japan
VYJUVEK delivers COL7A1 for DEB wounds. U.S. use includes patients from birth; the product is also approved in Europe, the U.K. and Japan. Germany launched August 2025; France and Japan October 2025. Italy is expected early 2027 after pricing completion. Q3 2026 Form 10-Q · November 2 VYJUVEK U.S. prescribing information VYJUVEK EU product information
Q3 revenue: U.S. $95.323M, Europe $23.256M, Japan $8.762M. Nine-month U.S. sales were $274.445M versus $277.145M a year earlier, while global sales rose. Q3 2026 Form 10-Q · November 2
KRYS gene therapy pipeline: distinct evidence stages
KB111 HALITE-1 has five enrolled patients and interim expected by year-end. KB113 showed lesion regression in a three-patient Gorlin pilot. KB803 IOLITE expects last visit February 2027; KB801 EMERALD-1 now targets enrollment completion and topline in 2027. Q3 results and pipeline timing · November 2 Q3 2026 Form 10-Q · November 2
KB407 interim moved to H1 2027; KB408 repeat-dose data are expected in 2027. KB707 combinations remain early clinical development, with approximately seventy patients targeted at the selected chemotherapy regimen by mid-2027. Jeune plans KB304 Phase 2 in 2027. Q3 results and pipeline timing · November 2
KRYS earnings, cash and capital allocation
Q3 net income fell to $63.068M from $79.365M because the prior comparison benefited from tax effects, while operating income increased to $71.145M from $41.374M. SG&A includes a $3M insurance reimbursement of legal costs. Q3 2026 Form 10-Q · November 2
September resources comprise cash $462.841M, short-term investments $449.010M and long-term investments $282.301M. Nine-month operating cash generation was $246.420M. The $400M repurchase program is authorized, discretionary and without a formal expiration. Q3 2026 Form 10-Q · November 2
Merlintrader Health Score · KRYS
4.20out of 5
Weighted calculation: 5.0 × 30% + 3.5 × 30% + 4.0 × 20% + 4.0 × 10% + 4.5 × 10% = 4.20 out of 5. Editorial assessment as of November 12, 2026. Weights: financial position 30%, catalysts 30%, dilution 20%, trading liquidity 10%, execution 10%. Not an investment recommendation or probability of clinical success.
KRYS red flags
- Single-product revenue concentration, despite geographic expansion. Q3 2026 Form 10-Q · November 2
- Small uncontrolled clinical cohorts cannot establish broad efficacy. Q3 2026 Form 10-Q · November 2
- KB407, KB803 and KB801 have revised development windows. Q3 results and pipeline timing · November 2
- Equity awards can dilute ownership; repurchases are discretionary. Q3 2026 Form 10-Q · November 2
- DOJ subpoenas concerning genetic testing and commercial practices are disclosed; the company is cooperating and cannot estimate potential loss. Q3 2026 Form 10-Q · November 2
KRYS Stock FAQ: Krystal Biotech Questions Answered
When is the next KRYS stock catalyst?
As of November 12, 2026, Krystal expects KB111 HALITE-1 interim results before year-end. The separate FDA meeting is expected Q1 2027. Before that window closes, management is scheduled to present at Jefferies on November 17; the conference is not a promised trial readout. Q3 results and pipeline timing · November 2 Investor conference schedule · November 10
Is Krystal Biotech VYJUVEK FDA approved?
As of November 12, 2026, VYJUVEK is FDA approved for wounds in adult and pediatric patients with DEB and COL7A1 mutations, including use from birth. The October 21 supplement concerns storage and handling. The other pipeline programs remain investigational. VYJUVEK U.S. prescribing information Q3 2026 Form 10-Q · November 2 FDA storage-and-handling supplement · October 21
How much cash does Krystal Biotech have?
At September 30, 2026, Krystal held $1,194.152M in cash and investments. Its funding statement uses $911.851M of cash and short-term investments for at least twelve months of planned operations. Nine-month operating cash generation was $246.420M. Q3 2026 Form 10-Q · November 2
Is KRYS stock exposed to dilution?
At September 30, 2026, outstanding options, RSUs and PSUs totaled 2,346,704. Common shares were 29,633,472 on October 28. The board authorized up to $400M of repurchases, without a requirement to complete purchases or a fixed expiration date. Q3 2026 Form 10-Q · November 2
When did Krystal Biotech report Q3 2026 earnings?
Krystal reported Q3 2026 results on November 2, 2026. VYJUVEK net revenue was $127.341M, operating income $71.145M and net income $63.068M. The full-year expense forecast is $155–165M combined non-GAAP R&D and SG&A, excluding stock compensation. Q3 2026 Form 10-Q · November 2 Q3 results and pipeline timing · November 2
What does Krystal Biotech do?
As of November 12, 2026, Krystal develops, manufactures and commercializes genetic medicines using an engineered HSV-1 platform. VYJUVEK treats DEB wounds; clinical programs address skin, eye and lung diseases, oncology and aesthetics through wholly owned Jeune. Q3 2026 Form 10-Q · November 2
When will Krystal Biotech report KB407 data?
The November 2, 2026 update places repeat-dose KB407 interim data in H1 2027. Three patients were receiving treatment, with another three expected before year-end. A registrational start is planned in 2027 after alignment on study design. Q3 results and pipeline timing · November 2
Are Krystal Biotech VYJUVEK sales growing in every region?
In the nine months ended September 30, 2026, global revenue rose to $362.920M, but U.S. revenue declined to $274.445M from $277.145M. Europe contributed $63.216M and Japan $25.259M. The global increase therefore includes substantial international launch revenue. Q3 2026 Form 10-Q · November 2
Primary sources
- Q3 2026 Form 10-Q · November 2
- Q3 results and pipeline timing · November 2
- 2025 Form 10-K
- VYJUVEK U.S. prescribing information
- FDA storage-and-handling supplement · October 21
- VYJUVEK EU product information
- KB113 pilot disclosure · October 15
- HALITE-1 trial record
- IOLITE trial record
- EMERALD-1 trial record
- CORAL-1 trial record
- SERPENTINE-1 trial record
- KYANITE-1 trial record
- Investor conference schedule · November 10
- Japan launch and historical list price · October 22, 2025
- Proxy · April 3; historical ownership and governance
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $KRYS or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, ClinicalTrials.gov and market data, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.
Clinical-stage biotechnology companies carry high execution, regulatory and financing risk. Trials fail, endpoints miss, enrollment slips, regulators ask for more data or decline to file an application, and companies that spend ahead of revenue raise equity at whatever price the market will bear. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate. Investors may lose part or all of their capital.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



